Abstract:Aims/hypothesisSystemic fibroblast growth factor (FGF)21 levels and hepatic FGF21 production are increased in non-alcoholic fatty liver disease patients, suggesting FGF21 resistance. We examined the effects of exenatide on FGF21 in patients with type 2 diabetes and in a diet-induced mouse model of obesity (DIO).MethodsType 2 diabetes mellitus patients (n = 24) on diet and/or metformin were randomised (using a table of random numbers) to receive additional treatment consisting of pioglitazone 45 mg/day or combined therapy with pioglitazone (45 mg/day) and exenatide (10 μg twice daily) for 12 months in an open label parallel study at the Baylor Clinic.ResultsTwenty-one patients completed the entire study and were included in the analysis. Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3.7 kg); plasma FGF21 levels did not change (1.9 ± 0.6 to 2.2 ± 0.6 ng/ml [mean±SEM]). However, combined pioglitazone and exenatide therapy (n = 11) was associated with a significant reduction of FGF21 levels (2.3 ± 0.5 to 1.1 ± 0.3 ng/ml) and a greater decrease in hepatic fat. Besides weight gain observed in the pioglitazone-treated patients, lower extremity oedema was observed as a side effect in two of the ten patients. Three patients who received pioglitazone and exenatide combination therapy complained of significant nausea that was self-limiting and did not require them to leave the study. In DIO mice, exendin-4 for 4 weeks significantly reduced hepatic triacylglycerol content, decreased hepatic FGF21 protein and mRNA, and enhanced phosphorylation of hepatic AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase, although no significant difference in weight and body fat was observed. Hepatic FGF21 correlated inversely with hepatic AMPK phosphorylationConclusions/interpretationIn type 2 diabetes mellitus, combined pioglitazone and exenatide therapy is associated with a reduction in plasma FGF21 levels, as well as a greater decrease in hepatic fat than that achieved with pioglitazone therapy. In DIO mice, exendin-4 treatment reduces hepatic triacylglycerol and FGF21 protein, and enhances hepatic AMPK phosphorylation, suggesting an improvement of hepatic FGF21 resistance.Trial registration number: ClinicalTrials.gov NCT 01432405Funding: American Diabetes Association, the Ron MacDonald Foundation at St Luke’s Episcopal Hospital, Amylin Pharmaceuticals, Eli-Lilly, NIH Molecular Medicine Scholars Training Grant, NIH Diabetes and Endocrinology Research Center (DERC) at Baylor College of Medicine, and the T.T. and W.F. Chao Foundation.

Exenatide Treatment Decreases Fasting Fibroblast Growth Factor 21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Effect of Exenatide on serum fibroblast growth factor-21 level in patients with type 2 diabetes

High Baseline FGF21 Levels Are Associated with Poor Glucose-Lowering Efficacy of Exenatide in Patients with Type 2 Diabetes

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Liver-derived Fibroblast Growth Factor 21 Mediates Effects of Glucagon-Like Peptide-1 in Attenuating Hepatic Glucose Output

Elevated Fibroblast Growth Factor-21 Protect Endothelial Function in Type 2 Diabetes Patients

Exenatide Treatment Increases Serum Irisin Levels in Patients with Obesity and Newly Diagnosed Type 2 Diabetes.

Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.

Effect of Baseline -Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

Effects of Exenatide Therapy on Insulin Resistance in the Skeletal Muscles of High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats.

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

Serum FGF-21 levels in type 2 diabetic patients.

Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.

962-P: Impacts of Different Hypoglycemic Agents on Adipokines and Inflammatory Markers in Newly Diagnosed T2D Patients

966-P: Effect of Baseline SS-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

Comparison of Changes in Adipokine and Inflammatory Cytokine Levels in Patients with Newly Diagnosed Type 2 Diabetes Treated with Exenatide, Insulin, or Pioglitazone: a Post-Hoc Study of the CONFIDENCE Trial